Search results for "EMA EPAR|DISEASES|BLOOD AND LYMPHATIC DISEASES|HEMOLOGIC DISEASES|BONE MARROW DISEASES" in comments (approximate match)
Showing 1 - 7 of 7 results
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Azacitidine (Vidaza; Pharmion), an inhibitor of DNA methylation, was approved by the US FDA for the treatment of myelodysplastic syndromes in May 2004. It is the first drug to be approved by the FDA for treating this rare family of bone-marrow disord...
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Ruxolitinib (trade names Jakafi and Jakavi, by Incyte Pharmaceuticals and Novartis) is a drug for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow. It is also being investiga...
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Nilotinib (AMN107, trade name Tasigna) is a kinase inhibitor indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia (CML) in adult patients resistant to or intolerant to prior ...
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Dasatinib [BMS 354825] is an orally active, small molecule, dual inhibitor of both SRC and ABL kinases that is under development with Bristol-Myers Squibb for the treatment of patients with chronic myelogenous leukaemia (CML) and imatinib-acquired re...
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Imatinib (GLEEVEC®) is a tyrosine kinase inhibitor and antineoplastic agent that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukaemia (CML). It...